Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Volociximab · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | Volociximab (10 mg/kg every other week (qowk)) and Gemcitabine |
| Cohort 2 | EXPERIMENTAL | Volociximab (15 mg/kg weekly (qwk)) and Gemcitabine |
| Name | Type | Description |
|---|---|---|
| Volociximab | DRUG | Volociximab: 10 mg/kg or 15mg/kg every week or every other week (qowk) via IV infusion for up to 104 weeks. |
| Gemcitabine | DRUG | Gemcitabine: Standard chemotherapy regime at 1 g/m2 once per week for 3 weeks via IV infusion, followed by one week with no treatment |
Inclusion Criteria: * Male or female, 18 years of age or older. * Histologically or cytologically confirmed metastatic adenocarcinoma of the pancreas. * May have received prior immunotherapy (including monoclonal antibodies) or vaccine therapies. * Measurable disease, according to RECIST criteria. ...
Top 20 of 69 competitors
Volociximab was studied for the treatment of metastatic pancreatic cancer. It was evaluated in combination with gemcitabine in a Phase 2 clinical trial in adults with this disease. Volociximab is an investigational monoclonal antibody and is not an approved therapy for pancreatic cancer or any other indication.
Volociximab targets the integrins ITGB1 and ITGA5. It acts as an antagonist, meaning it blocks rather than activates these targets. By binding ITGB1 and ITGA5, the antibody interferes with integrin-mediated signaling. This mechanism was the basis for studying volociximab in pancreatic cancer, where integrin activity is thought to support tumor growth and survival.
Volociximab was developed by AbbVie Inc., which trades on the New York Stock Exchange under the ticker ABBV. AbbVie sponsored the clinical research program for the drug, including the Phase 2 study in metastatic pancreatic cancer. The asset is an investigational monoclonal antibody in the oncology therapeutic area.
Volociximab is in Phase 2 development. It has not been approved by the FDA or any other regulatory agency and remains an investigational agent. Only one clinical trial has been conducted, and that study is now completed. No active trials of volociximab are currently listed.
Volociximab was evaluated in one completed Phase 2 trial, NCT00401570, titled A Study of Volociximab in Combination With Gemcitabine in Metastatic Pancreatic Cancer. The trial enrolled 40 adults aged 18 years and older across the United States and the United Kingdom. It used a controlled design and was not randomized or double blinded.